^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RPM CD19-mbIL15-CAR-T cells

    i
    Other names: RPM CD19-mbIL15-CAR-T cells, CAR CD19 3rd gen CAR with mbIL15 (P-O-C), CD19-mbIL15-chimeric antigen receptor [CAR]-T cells, CAR CD19 3rd gen CAR with mbIL15 (Point of care), P-O-C CD19-mbIL15-chimeric antigen receptor [CAR]-T cells, autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-EGFRt T cells, CD19-CD8CD28zCAR-specific-mbIL15-HER1t T lymphocytes, autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells, CD19+ specific chimeric antigen receptor T cells, CD19-specific T cells expressing membrane-bound form of IL-15, CD19RCD28
    Associations

    News

    Trials
    Company:
    Alaunos Therap, Eden BioCell, UT MD Anderson Cancer Center
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over2years
    RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=2, Terminated, Eden BioCell Ltd. | N=24 --> 2 | Trial completion date: Oct 2036 --> May 2022 | Recruiting --> Terminated | Trial primary completion date: Oct 2022 --> May 2022; CAR-T manufacturing technology can not meet the dose requirement for clinical patients.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    CD19 expression
    |
    cyclophosphamide • RPM CD19-mbIL15-CAR-T cells
    over3years
    CD19-Specific T Cells Post AlloSCT (clinicaltrials.gov)
    P1, N=4, Terminated, M.D. Anderson Cancer Center | N=24 --> 4 | Trial completion date: Nov 2021 --> May 2021 | Recruiting --> Terminated | Trial primary completion date: Nov 2021 --> May 2021; Study halted prematurely
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    fludarabine IV • RPM CD19-mbIL15-CAR-T cells • cyclophosphamide intravenous
    over3years
    RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=24, Recruiting, Eden BioCell Ltd.
    Clinical • New P1 trial • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    CD19 expression
    |
    RPM CD19-mbIL15-CAR-T cells
    over4years
    CD19-Specific T Cells Post AlloSCT (clinicaltrials.gov)
    P1, N=24, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD19 (CD19 Molecule)
    |
    fludarabine IV • RPM CD19-mbIL15-CAR-T cells • cyclophosphamide intravenous